Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, dose-escalation Phase I study to determine the maximum
tolerated dose (MTD) of G-202 (mipsagargin) when administered once daily for 3 consecutive
days of a 28-day cycle in patients with advanced solid tumors. G-202 will be administered by
intravenous infusion over 1 hour on Days 1, 2 and 3 of each 28-day cycle.